



Deposited via The University of Sheffield.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/175395/>

Version: Accepted Version

Article:

Kruszka, P., Berger, S.I., Casa, V. et al. (2019) Cohesin complex-associated holoprosencephaly. *Brain*, 142 (9). pp. 2631-2643. ISSN: 0006-8950

<https://doi.org/10.1093/brain/awz210>

This is a pre-copyedited, author-produced version of an article accepted for publication in *Brain* following peer review. The version of record Paul Kruszka, Seth I Berger, Valentina Casa, Mike R Dekker, Jenna Gaesser, Karin Weiss, Ariel F Martinez, David R Murdock, Raymond J Louie, Eloise J Prijoles, Angie W Lichty, Oebele F Brouwer, Evelien Zonneveld-Huijssoon, Mark J Stephan, Jacob Hogue, Ping Hu, Momoko Tanima-Nagai, Joshua L Everson, Chitra Prasad, Anna Cereda, Maria Iascone, Allison Schreiber, Vickie Zurcher, Nicole Corsten-Janssen, Luis Escobar, Nancy J Clegg, Mauricio R Delgado, Omkar Hajirnis, Meena Balasubramanian, Hülya Kayserili, Matthew Deardorff, Raymond A Poot, Kerstin S Wendt, Robert J Lipinski, Maximilian Muenke, Cohesin complex-associated holoprosencephaly, *Brain*, Volume 142, Issue 9, September 2019, Pages 2631–2643 is available online at: <https://doi.org/10.1093/brain/awz210>

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

Cohesin Complex-Associated Holoprosencephaly

Paul Kruszka¹, Seth I. Berger^{1,23}, Valentina Casa², Mike R. Dekker², Jenna Gaesser³, Karin Weiss^{1,24}, Ariel F. Martinez¹, David R. Murdock^{1,25}, Raymond J. Louie⁴, Eloise J. Prijoles⁴, Angie W Lichty⁴, Oebele F. Brouwer⁵, Evelien Zonneveld-Huijssoon⁶, Mark J. Stephan⁷, Jacob Hogue⁸, Ping Hu¹, Momoko Tanima-Nagai¹, Joshua L. Everson^{9,10}, Chitra Prasad¹¹, Anna Cereda¹², Maria Iascone¹³, Allison Schreiber¹⁴, Vickie Zurcher¹⁴, Nicole Corsten-Janssen⁶, Luis Escobar¹⁵, Nancy J. Clegg¹⁶, Mauricio R. Delgado^{16,17}, Omkar Hajirnis¹⁸, Meena Balasubramanian¹⁹, Hülya Kayserili²⁰, Matthew Deardorff^{21,22}, Raymond A. Poot², Kerstin S. Wendt², Robert J. Lipinski^{9,10}, Maximilian Muenke¹

¹Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA

²Department of Cell Biology, Erasmus MC, Rotterdam, The Netherlands

³Department of Pediatrics, Division of Neurology, University of Pittsburgh, Pittsburgh, PA, USA

⁴Greenwood Genetic Center, JC Self Research Institute of Human Genetics, Greenwood, SC, USA

⁵Department of Neurology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

⁶Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands

⁷Department of Pediatrics, University of Washington, Seattle, WA, USA

⁸Division of Clinical Genetics, Department of Pediatrics, Madigan Army Hospital, Tacoma, WA, USA

⁹Department of Comparative Biosciences, School of Veterinary Medicine, University of Wisconsin-Madison, Madison, WI, USA

¹⁰Molecular and Environmental Toxicology Center, School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI, USA

¹¹Children's Health Research Institute, London, N6A 5W9, ON, Canada

¹²Department of Pediatrics, ASST Papa Giovanni XXIII, Bergamo, Italy

¹³Laboratorio di Genetica Medica, ASST Papa Giovanni XXIII, Bergamo, Italy

¹⁴Genomic Medicine Institute, Cleveland Clinic, Cleveland, OH, USA

¹⁵Peyton Manning Children's Hospital at St. Vincent, Medical Genetics & Neurodevelopment Center, Indianapolis, IN, USA

¹⁶Texas Scottish Rite Hospital for Children, Dallas, TX, USA

¹⁷Department of Neurology and Neurotherapeutics UT Southwestern Medical Center Dallas, TX, USA

¹⁸Pediatric Neurology, Synapses Child Neurology & Development Centre, Thane, Maharashtra, India

¹⁹Sheffield Clinical Genetics Service, Sheffield Children's, National NHS Foundation Trust, Sheffield, United Kingdom

²⁰Medical Genetics, Medical Faculty, Koç University, Istanbul, Turkey

²¹The Division of Genetics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA

²²The Department of Pediatrics, The Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, USA

²³Center for Genetic Medicine Research, Children National Health System, Washington, DC (present address)

²⁴Genetics Institute, Rambam Health Care Campus, Haifa, Israel (present address)

²⁵Baylor College of Medicine, Houston, TX, USA

Correspondence: Maximilian Muenke, MD, 35 Convent Drive, Building 35 Room 1B203, Bethesda, MD 20892; mamuenke@mail.nih.gov and Paul Kruszka, MD, 35 Convent Drive, Building 35 Room 1B207, Bethesda, MD 20892; paul.kruszka@nih.gov

ABSTRACT

Marked by incomplete division of the embryonic forebrain, holoprosencephaly is one of the most common human developmental disorders. Despite decades of phenotype driven research, 80-90% of aneuploidy-negative holoprosencephaly individuals with a probable genetic etiology do not have a genetic diagnosis. Here we report holoprosencephaly associated with variants in the two X-linked cohesin complex genes, *STAG2* and *SMC1A*, with loss-of-function variants in 10 individuals and a missense variant in one. Additionally, we report four individuals with variants in the cohesin complex genes that are not X-linked, *SMC3* and *RAD21*. Using whole mount *in situ* hybridization, we show that *STAG2* and *SMC1A* are expressed in the prosencephalic neural folds during primary neurulation in the mouse, consistent with forebrain morphogenesis and holoprosencephaly pathogenesis. Finally, we found that shRNA knockdown of *STAG2* and *SMC1A* causes aberrant expression of HPE-associated genes *ZIC2*, *GLI2*, *SMAD3*, and *FGFR1* in human neural progenitor cells. These findings show the cohesin complex as an important regulator of median forebrain development and X-linked inheritance patterns in holoprosencephaly.

Keywords

Holoprosencephaly, cohesin complex, X-linked inheritance, forebrain division

Introduction

Holoprosencephaly (HPE) is defined by incomplete division of the embryonic forebrain. While occurring in approximately 1 in 10,000 live births, HPE is estimated to occur in 1 in 250 embryos, making it one of the most common human developmental abnormalities (Matsunaga and Shiota, 1977). The most common cause is trisomy 13 which accounts for roughly 50% of all cases (Kruszka, 2018). Over the last two decades, four principal genes have been associated with HPE: *SHH* at 7q36.3, *ZIC2* at 13q32.3, *SIX3* at 2p21, and *TGIF1* at 18p11.31. These 4 genes have been the mainstay for genetic testing in individuals with HPE and normal karyotypes (Pineda-Alvarez *et al.*, 2010; Kruszka *et al.*, 2018). At least 10 other genetic loci have associated with HPE, but at a lower prevalence (Kruszka *et al.*, 2018). *SHH*, *SIX3*, *ZIC2* and *TGIF1* account for only a fraction of the genetic etiology in individuals with normal karyotypes. In a recent next generation sequencing study of 257 individuals with HPE, deleterious variants in *SHH* was most common in 5.8% of the HPE cohort, *ZIC2* at 4.7% , *SIX3* at 2.7% and no deleterious variants in *TGIF1* (Dubourg *et al.*, 2016); collectively, these four genes accounted for 13.2% of the etiology in these individuals. With the introduction of whole exome sequencing, driver mutations in new genes including *FGFR1* and *CNOT1* are being found (Simonis *et al.*, 2013; De Franco *et al.*, 2019; Kruszka *et al.*, 2019). To expand the genetic etiology of HPE and uncover novel regulators of forebrain development, we have applied whole exome sequencing (WES) to 277 probands with HPE and both their parents (trios), if available.

We initially identified loss of function variants in cohesin complex genes in 5 of 277 (1.8%) individuals in our holoprosencephaly cohort at the National Institutes of Health (NIH). Through our research network and GeneMatcher (Sobreira *et al.*, 2015), we identified 10 other individuals

with holoprosencephaly and variants in cohesin complex genes. Collectively, these 15 individuals with HPE have 13 loss of function (LOF) variants, one in-frame deletion, and one pathogenic missense variant distributed across the four cohesin complex genes *SMC1A* [MIM: 300040], *STAG2* [MIM: 300826], *SMC3* [MIM: 606062], and *RAD21* [MIM: 606462]. The majority of cases (11/15) are females with variants in the X-linked genes *SMC1A* and *STAG2*. Cohesin is a highly conserved multiprotein complex with *SMC1A*, *SMC3*, *RAD21* and *STAG1/STAG2* as its subunits in mammals (Brooker and Berkowitz, 2014). This complex forms a ring structure that is involved in sister chromatid cohesion during DNA replications. Additional roles of this complex include transcription regulation and DNA repair (Mehta *et al.*, 2013). Mutations in the cohesin complex and its regulators have been associated with four human genetic syndromes: Cornelia de Lange syndrome (CdLS) caused by variants in *NIPBL* (Krantz *et al.*, 2004), *SMC1A* (Musio *et al.*, 2006), *SMC3* (Deardorff *et al.*, 2007), *RAD21* (Deardorff *et al.*, 2012b), *BRD4* (Olley *et al.*, 2018), and *HDAC8* (Deardorff *et al.*, 2012a); Roberts syndrome caused by mutations in *ESCO2* (Gordillo *et al.*, 2008), CHOPS syndrome (Cognitive impairment and coarse facies, Hear defects, Obesity, Pulmonary involvement, and Short stature and skeletal dysplasia) associated with *AFF4* variants (Izumi *et al.*, 2015); and Chronic Atrial and Intestinal Dysrhythmia caused by mutations in *SGOL1* (Chetaille *et al.*, 2014). The cohesin complex genes that we associate with holoprosencephaly (*STAG2*, *SMC1A*, *SMC3*, and *RAD21*) are intolerant of variation based on the Genome Aggregation Database (gnomAD) constraint metric of observed/expected loss of function (o/e) values (Lek *et al.*, 2016). Values less than 0.35 (o/e) are considered under selection against LOF (<https://gnomad.broadinstitute.org>) and the cohesin complex genes were well below this

threshold: *STAG2* 0.02 (90%CI, 0.1-0.09), *SMC1A* 0.0 (90%CI, 0.0-0.06), *SMC3* 0.0 (90%CI, 0.0-0.04), and *RAD21* 0.1 (90%CI, 0.04-0.26).

Materials and methods

Subjects and clinical phenotyping

The individuals and families with HPE in this study were recruited from multiple clinical genetics centers internationally. Within the participating institutions, the phenotype was evaluated by clinical exam by the authors of this study and brain imaging (MRI or CT) or autopsy to confirm holoprosencephaly. The study was approved by National Human Genome Research Institute Institutional Review Board (IRB) and the ethical committee of the patient's local institutions. The subjects' consents were obtained according to the Declaration of Helsinki.

DNA Sequence analysis

Sanger sequencing

With the goal of new gene discovery, probands were prescreened for four common genes known to cause HPE: *SHH* [MIM 600725] on 7q36, *ZIC2* [MIM 603073] on 13q32, *SIX3* [MIM 603714] on 2p21, and *TGIF1* [MIM 602630] on 18p11.3 using Sanger sequencing (Supplementary Methods). Novel variants found in this study by whole exome sequencing were also confirmed with Sanger sequencing.

Whole exome sequencing

Whole exome sequencing (WES) was performed at NISC on the individuals from the NIH HPE cohort (see Supplementary Methods). The remaining individuals were sequenced at six other

academic and commercial laboratories (laboratory locations listed in Supplementary Table 4). All WES results were verified by Sanger sequencing. Stringent variant filtering of the NIH cohort included: (1) *de novo* inheritance of variants in genes known to be intolerant of variation (Lek *et al.*, 2016), (2) absence in the ExAC data base (Lek *et al.*, 2016), and (3) Combined Annotation-Dependent Depletion (CADD) scores above 20 (Kircher *et al.*, 2014).

Mouse embryo *in situ* hybridization

Genes that contribute to median forebrain morphogenesis and HPE pathogenesis are expressed in the prosencephalic neural folds that give rise to the forebrain during primary neurulation (Roessler, 2018). We therefore examined expression of *Stag2* and *Smc1a* by *in situ* hybridization (ISH) on mouse embryos at GD8.25 (Supplementary methods), a stage representing early neurulation and within the critical period for HPE genesis (Heyne *et al.*, 2015a). ISH was conducted as previously described and analysis was limited to the prosencephalic regions of the neural fold from which the forebrain will develop (Everson *et al.*, 2017). This study was conducted in strict accordance with the recommendations in the *Guide for the Care and Use of Laboratory Animals* of the National Institutes of Health. The protocol was approved by the University of Wisconsin-Madison School of Veterinary Medicine Institutional Animal Care and Use Committee (protocol number 13-081.0). CD-1 mice (*Mus musculus*) were purchased from Charles River and C57BL/6J mice from The Jackson Laboratory. Timed-pregnancies were established as previously described (Heyne *et al.*, 2015b). Embryos were dissected at GD8.25 and fixed overnight in 4% PFA. *In situ* hybridization (ISH) was conducted on whole C57BL/6J embryos or 50 μm sections cut from CD-1 embryos with a vibrating microtome in the transverse plane along the anterior-posterior axis. ISH was conducted as

previously described (Everson *et al.*, 2017).

Gene expression studies in human neural progenitor cells

In order to test the hypothesis that variation in cohesin genes, specifically *STAG2* and *SMC1A*, perturb known forebrain developmental pathways, we measured selected gene expression associated with these pathways. First, knockdown of *STAG2* and *SMC1A* with shRNA was performed on human neural stem cells (Supplementary Methods; Figure S1). Known HPE pathways were analyzed at the gene expression level with RT-qPCR of *SHH*, *SIX3*, *FGFR1*, *GLI2*, *ZIC2*, *GLI2*, *SMAD3* and *DISP1* genes.

Data availability

The raw data that supports the findings of this manuscript are available upon request to the corresponding author.

Results

Patients: phenotype and genotype

We assembled 277 individuals with HPE in our NIH cohort (135 trios and 142 singletons); the cohort characteristics are shown in Supplementary Table 1. In the four classic HPE genes, pathogenic variants were found in 33 (11.9%) individuals: *ZIC2* was most common with 15 (5.4%) variants, followed by *SHH* 9 (3.2%), *SIX3* 8 (2.9%), and *TGIF1* 1 (0.4%). For these four genes, Supplementary Table 2 lists each variant, HPE subtype and inheritance pattern. In our HPE cohort of 277 individuals at NIH, four females had truncating mutations (four nonsense and one splice site) in the cohesin complex genes *STAG2* and *SMC1A* on the X chromosome, and one

proband had a nonsense variant in *RAD21* (Table 1-4). Another four LOF variants in *STAG2* in females, two LOF variants and one missense variant in *SMC1A* all in females, a LOF in *RAD21*, and an in-frame deletion in *SMC3* were found through our group's holoprosencephaly network, DECIPHER (Firth *et al.*, 2009) and GeneMatcher (Sobreira *et al.*, 2015) (Table 1; Supplementary Case Reports).

STAG2

The phenotypes of four of six patients with *STAG2* pathogenic variants in the present study included the most severe forms of HPE: alobar HPE with cyclopia, alobar without cyclopia, and semilobar HPE (patients 1-4 Table 1-2). The other two patients with *STAG2* variants had milder forms of HPE (patients 5-6 Table 1): patient 5 had microform HPE which is characterized by midline clefting, hypotelorism and depressed nasal bridge without brain anomalies (Figure 1B), and patient 6 is classified with septo-optic dysplasia type of HPE (Hahn *et al.*, 2010) based on ophthalmology exam showing optic nerve hypoplasia and MRI findings of mildly dysmorphic neurohypophysis. In Table 2, we compare the genotypes and phenotypes of the 6 cases in the present study with 6 cases with LOF variants from the medical literature (Mullegama *et al.*, 2017; Aoi *et al.*, 2019; Yuan *et al.*, 2019). Overlapping clinical features of the 6 individuals in the present study and the 6 individuals in the medical literature include two of the six cases from the medical literature with HPE: patient 1 from Aoi *et al.* has a structural brain malformation consistent with HPE, and patient 3 from Yuan *et al.* has the microform HPE subtype. Microform HPE is the least severe form of HPE characterized by midline defects such as a single central incisor without the typical defect in brain cleavage. Additionally, three of the four cases in the medical literature have midline brain malformations including HPE as noted above, agenesis of

the corpus callosum, and dysgenesis of the corpus callosum. Most of the present study and the cases in the medical literature have vertebral anomalies: 6 of 7 that reported spine anomalies. Vertebral anomalies are not part of the clinical features associated with CdLS, but are commonly found in individuals with variants in *SMC3* and *RAD21* (Kline *et al.*, 2018). Also, 7 of 9 total had congenital heart disease. All LOF *STAG2* variants in the medical literature are *de novo*; interestingly, in the present study, patient 4, (1/5) is inherited maternally which may be explained by skewed X-inactivation (not tested) or incomplete penetrance. Additionally, there is a loss of function variant in the gnomAD database of presumptively healthy individuals (allele count 1/178,804) which raises the possibility of the rare case of incomplete penetrance (<https://gnomad.broadinstitute.org> accessed May 1, 2019). Collectively from the 12 cases from the present study and medical literature with LOF variants in *STAG2*, only one individual is male and he is reported to have HPE (Aoi *et al.*, 2019); the most likely conclusion is that LOF variants in *STAG2* are lethal or result in the most severe phenotype (HPE). Coincidentally, Mullegama *et al.* reported a patient with a *STAG2* with an identical variant as in patient 2 (Figure 1), c.205 C>T; p.Arg69* (Mullegama *et al.*, 2017). The patient in the Mullegama report had dysgenesis of the splenium of the corpus callosum and the patient in this study had semilobar HPE, showing that *STAG2* loss of function variants are responsible for a spectrum of midline brain anomalies.

SMCIA

The other five individuals with X-linked HPE were all females (Patients 7-11; Table 3; Figure) with four truncating variants and one with a missense variant in *SMCIA*, a cohesin complex gene known to be associated Cornelia de Lange syndrome (CdLS) (Deardorff *et al.*, 2007). Variants in *SMCIA* account for 4-6% of individuals with CdLS (12-14 Jansen)(Ansari *et al.*, 2014; Boyle

et al., 2015; Yuan *et al.*, 2015) and are most commonly missense and in-frame deletions (Huisman *et al.*, 2013). Four of five individuals in the present study have LOF variants; therefore, we have used 16 cases with LOF variants in *SMCIA* in the medical literature with phenotype information for comparison in Table 3 (Hoppman-Chaney *et al.*, 2012; Goldstein *et al.*, 2015; Lebrun *et al.*, 2015; Jansen *et al.*, 2016; Symonds *et al.*, 2017). The most severe phenotype in the LOF variants in the medical literature was holoprosencephaly found in 2 of 16 individuals (Hoppman-Chaney *et al.*, 2012; Symonds *et al.*, 2017). In both the present study and in the medical literature, when parents were available, all LOF variants were *de novo* and all individuals were females. In addition to midline brain defects, the most striking phenotype is seizure disorders. In the present study, 4 of 5 individuals had seizures and 15 of 16 in the medical literature. In the largest study of 10 individuals with truncating variants in *SMCIA*, 9 of the 9 reporting seizures had severe drug resistant epilepsy (Symonds *et al.*, 2017). All 16 cases of the present study and medical literature had developmental delay. Two individuals in the present study have facial characteristics consistent with mild CdLS, patients 9 and 10 both have synophrys and small hands. In the largest study of LOF variants in *SMCIA* (Table 3), the authors report few phenotype characteristics consistent with CdLS (Symonds *et al.*, 2017).

RAD21

Four variants were found in the two cohesin complex genes that are not X-linked, three were in the gene *RAD21*. The three *RAD21* variants (Patient 12 and 13; Table 4) were loss of function; interestingly, patient 12 with the c.1548delinsTC p.(Glu518Argfs*19) variant in *RAD21* is an inherited variant in this study with the father having the same variant, synophrys, and a submucous cleft palate. The three LOF variants in the present study are compared to LOF and

deletions involving *RAD21* in the medical literature (Wuyts *et al.*, 2002; McBrien *et al.*, 2008; Deardorff *et al.*, 2012b; Minor *et al.*, 2014; Boyle *et al.*, 2017). A much higher fraction of LOF variants are inherited compared to *STAG2* and *SMC1A*: present study 1 (1/1) and in the medical literature, 2 of 5 (when parents were available). Both the present study and the medical literature presented individuals with cardinal features of CdLS (Kline *et al.*, 2018), including: synophrys or thick eyebrows in 7/9, short or upturned nose in 4/9, long philtrum 4/9, and microcephaly in 5/9.

SMC3

The fourth non-X linked gene is *SMC3* and the *SMC3* variant (Patient 15; Table 5) was a *de novo* in-frame deletion which is likely pathogenic (Richards *et al.*, 2015). In Table 5, we compare to the largest most comprehensive series of individuals with variants in *SMC3* (n=16) (Gil-Rodríguez *et al.*, 2015). The present study found an inframe deletion in *SMC3* in a fetus with semilobar HPE, median cleft lip, tetralogy of Fallot, hypospadias, anal atresia and limb anomalies. Gil-Rodríguez *et al.* found two of their study participants to have midline brain malformations: corpus callosum dysgenesis (2/11) and no cases of holoprosencephaly (Gil-Rodríguez *et al.*, 2015). Based on reviewing the present study's case and the cohort presented by Gil-Rodríguez *et al.* intellectual disability (13/13) and congenital heart disease (10/17) were prevalent. The facial features are difficult to characterize due to the early gestation in the present study (Figure); however, Gil-Rodríguez *et al.* found a majority of cases to have facial features consistent with CdLS (Table).

Mouse *in situ* hybridization

As a control, we first examined the expression of *Shh* (Figure 2), a gene with a well-characterized expression domain and role in forebrain patterning and HPE (Chiang *et al.*, 1996; Solomon *et al.*, 2012; Hong *et al.*, 2016). Expression of *Shh* is restricted to the ventromedial neuroectoderm (Figure 2) as previously described (Echelard *et al.*, 1993). Both *Smc1a* and *Stag2* are also strongly detected in the anterior neural folds with expression observed in both the neuroectoderm and adjacent mesenchyme (Figure 2). The specificity of the observed expression domains for these genes is supported by the absence of staining in extra-embryonic membrane tissue lateral to the neural folds.

Gene expression studies in human neural progenitor cells

As noted in the methods section, we analyzed the expression level of genes known to be involved in HPE pathways with RT-qPCR which include *SHH*, *SIX3*, *FGFR1*, *GLI2*, *ZIC2*, *GLI2*, *SMAD3* and *DISP1*. *SHH*, *SIX3*, *ZIC2*, and *FGFR1* were chosen as variants in these genes are known to cause HPE (Kruszka *et al.*, 2018; Kruszka, 2018). *DISP1* is part of the sonic hedgehog pathway and has been associated with HPE (Roessler *et al.*, 2009; Dubourg *et al.*, 2016); also part of the sonic hedgehog pathway, *GLI2* is an often HPE tested gene that is associated with HPE spectrum anomalies including pituitary insufficiency, midface hypoplasia, hypotelorism, and cleft lip/palate (Kruszka *et al.*, 2018). Although not known to contain driver mutations associated with HPE, *SMAD3* physically interacts with *ZIC2* and controls transcription in a *NODAL* dependent manner and variant forms of *ZIC2* associated with HPE in humans and the mouse have difficulty with *SMAD*-dependent transcription, making *SMAD3* of interest (Houtmeyers *et al.*, 2016). Compared to controls, *SMCIA* knockdown in human neural stem cells resulted in significantly increased expression in *GLI2* ($P < 0.01$), *ZIC2* ($P < 0.05$), and

SMAD3 ($P < 0.05$) (Figure 3). For *STAG2* knockdown (Figure 4), significantly increased expression was seen in *ZIC2* ($P < 0.0001$) and *FGFR1* ($P < 0.01$). Thus, there was over expression in *ZIC2* from knockdown of both *SMC1A* and *STAG2*. Similar to a previous experiment (Cotney *et al.*, 2015), *SHH* and *SIX3* expression was undetectable in H9-derived human neural stem cells ([ThermoFisher/Invitrogen, #N7800-100](#)).

Discussion

Holoprosencephaly research and clinical care has focused on sonic hedgehog pathway and the genes *SHH*, *ZIC2*, and *SIX3* for the last two decades (Roessler and Muenke, 2010; Roessler *et al.*, 2018). This study introduces new genes in the cohesin complex as important components of early forebrain division and the holoprosencephaly spectrum. Evaluating the holoprosencephaly study at the National Human Genome Research Institute with whole exome sequencing, five of 277 probands were identified with variants in cohesin complex genes. Ten additional individuals with holoprosencephaly were identified from other institutions. Eleven of the fifteen individuals had variants in the X-linked genes *STAG2* and *SMC1A*. *STAG2* has only recently been associated with human disease (Mullegama *et al.*, 2017; Soardi *et al.*, 2017; Aoi *et al.*, 2019; Mullegama *et al.*, 2019; Yuan *et al.*, 2019). A small number of cases with cohesin complex HPE have been reported in the medical literature in the past: two HPE cases with LOF variants in *STAG2* (Aoi *et al.*, 2019; Yuan *et al.*, 2019), two cases associated with *SMC1A* (Hoppman-Chaney *et al.*, 2012; Symonds *et al.*, 2017), and no HPE cases have been reported that we are aware in *RAD21* and *SMC3*. Knowing that all individuals with CdLS have not had brain imaging, the incidence of HPE associated with cohesinopathy genes may be more common than previously reported.

Interestingly, the 11 individuals in this study with *STAG2* and *SMC1A* variants are females, thus we propose that loss-of-function variants in the X-linked cohesin genes are usually lethal in males; certainly there are possible exceptions in males including mosaicism, 47,XXY, and gene duplications. Notably, *STAG2* undergoes complete X inactivation and *SMC1A* undergoes partial X-inactivation (Cotton *et al.*, 2013). For Patient 2 with a *STAG2* nonsense variant (c.205C>T p.(Arg69*)), X-inactivation studies were consistent with random X-inactivation, implying that haploinsufficiency is required for the HPE phenotype in *STAG2*. The one exception to LOF in *STAG2* and *SMC1A* is Patient 9; who had a missense variant (Table 1) is located in the conserved second coiled-coil domain and is likely pathogenic (Richards *et al.*, 2015). Based on the loss of function variants in *SMC1A* in the other four individuals in this report, we hypothesize that the *SMC1A* variant (c.2683C>G (p. Arg895Gly)) has a loss of function variant or a dominant negative effect. To evaluate X-linked inheritance from our HPE registry, we performed a binomial distribution on 700 individuals with HPE. Of these 700 individuals, 409 were female ($p= 0.000005$). If we subtract individuals with known pathogenic variants in *SHH*, *SIX3*, and *ZIC2*, there are 645 individuals, of whom, 378 are female ($p= 0.000015$). Although *STAG2* and *SMC1A* variation most likely does not explain this significant trend towards female sex in our registry, X-linked dominant inheritance likely plays an important role.

Previous study has shown that antagonizing the hedgehog signaling pathway between gestational days 7.0 and 8.25 of mouse development (between 15 and 18.75 days of human gestation) results in holoprosencephaly (Heyne *et al.*, 2015a). Since forebrain patterning genes are expected to be expressed in the prosencephalic neural folds during primary neurulation (Geng and Oliver,

2009), we assessed expression of cohesin complex genes during this critical period for holoprosencephaly in the mouse. The finding that both *Smc1a* and *Stag2* are expressed in the prosencephalic neural folds complements the human genetic evidence in this study and supports the role of cohesion complex genes in forebrain morphogenesis. Being expressed in both the neuroectoderm and adjacent mesenchyme suggests that the cohesion complex may interact with other critical regulators of forebrain patterning and HPE pathogenesis.

To further elucidate the relationship between forebrain division in early embryogenesis and the cohesin complex, we knocked down cohesin complex gene expression in human progenitor cells and measured canonical HPE gene expression. Upregulation in gene expression was seen in *GLI2*, *ZIC2* and *SMAD3* for *SMC1A* knockdown (Figure 3), and *ZIC2* and *FGFR1* for *STAG2* knockdown (Figure 4). Loss of function in *ZIC2* has been associated with HPE in the past and the mechanism of increased expression in *SMC1A* and *STAG2* knockdown human neural progenitor cells is not completely clear. In the mouse model, loss of function of *Zic2* results in the failure to activate specific genes in the mid-gastrula node including *Foxa2* which is required to activate *Shh* in the prechordal plate (Warr *et al.*, 2008). There is evidence in the *Xenopus* that over expression of *zic2* may contribute depletion of *foxa2* in the Spemann organizer (Houtmeyers *et al.*, 2016). Overexpression by injection of *zic2* mRNA into *Xenopus* embryos at the 4-8 cell stage resulted in reduced *foxa2* expression (Houtmeyers *et al.*, 2016). *SMAD3* is upregulated in *SMC1A* knockdown which is of interest as *SMAD3* and *ZIC2* physically interact with each other in cell culture (A549 cells) to occupy a binding site in the promoter region of *FOXA2* (Houtmeyers *et al.*, 2016). *FGFR1* expression increased in *STAG2* knockdown neural progenitor cells. *FGFR1* variants are associated with Hartsfield syndrome which has

holoprosencephaly and split hands and feet as phenotype elements. It is unclear how overexpression of *FGFR1* is related to holoprosencephaly as the mechanism of *FGFR1* in HPE is a dominant negative effect (Hong *et al.*, 2016). *GLI2* is overexpressed in the *SMC1A* knockdown neural progenitor cells. *GLI2* is both a transcriptional activator and repressor in the sonic hedgehog pathway (Sasaki *et al.*, 1999) and although it does not cause holoprosencephaly, loss of function variants in *GLI2* are associated with Culler-Jones syndrome which presents with hypopituitarism, polydactyly, and facial features often found in holoprosencephaly (Kruszka *et al.*, 2018).

In conclusion, we present 15 patients with holoprosencephaly spectrum malformations who have variants in cohesin complex genes *STAG2*, *SMC1A*, *SMC3*, and *RAD21*. Although the precise mechanism of abnormal forebrain development is unknown in loss of function variants in cohesin complex genes, *Stag2* and *Smc1a* are expressed in neural fold at the critical time of forebrain division in the mouse model. Additionally, we show that knockdown of *STAG2* and *SMC1A* in human neural progenitor cells perturbs known HPE genes. Currently, there are no cohesin complex or X-linked genes that are commonly tested for in individuals with holoprosencephaly (Kruszka *et al.*, 2018). This report of X-linked and cohesin complex holoprosencephaly has broad implications for future genetic testing, genetic counseling and HPE research.

Acknowledgements

We thank Dr. Seychelle M. Vos of the Max Planck Institute for Biophysical Chemistry for critical review of this manuscript. This study makes use of data generated by the DECIPHER

community. A full list of centres who contributed to the generation of the data is available from <http://decipher.sanger.ac.uk> and via email from decipher@sanger.ac.uk. Funding for the project was provided by the Wellcome Trust.

Funding

This work was supported by the National Human Genome Research Institute Intramural Research program. Work in the lab of K.S.W. was funded by the Dutch Cancer Society (KWF) grant EMCR 2015-7857 and by the by the Netherlands Organisation of Scientific Research (NWO) grant 737.016.014. Work in the R.J.L. lab was supported by the National Institute of Environmental Health Sciences of the National Institutes of Health under award numbers R01ES026819 and T32ES007015.

Competing Interests

The authors report no competing interests.

Supplementary material

Case reports, one figure, and methods

References

Ansari M, Poke G, Ferry Q, Williamson K, Aldridge R, Meynert AM, *et al.* Genetic heterogeneity in Cornelia de Lange syndrome (CdLS) and CdLS-like phenotypes with observed and predicted levels of mosaicism. *Journal of medical genetics* 2014; 51(10): 659-68.

Aoi H, Lei M, Mizuguchi T, Nishioka N, Goto T, Miyama S, *et al.* Nonsense variants in STAG2 result in distinct sex-dependent phenotypes. *J Hum Genet* 2019.

Boyle MI, Jespersgaard C, Brondum-Nielsen K, Bisgaard AM, Tumer Z. Cornelia de Lange syndrome. *Clin Genet* 2015; 88(1): 1-12.

Boyle MI, Jespersgaard C, Nazaryan L, Bisgaard AM, Tumer Z. A novel RAD21 variant associated with intrafamilial phenotypic variation in Cornelia de Lange syndrome - review of the literature. *Clin Genet* 2017; 91(4): 647-9.

Brooker AS, Berkowitz KM. The roles of cohesins in mitosis, meiosis, and human health and disease. *Methods Mol Biol* 2014; 1170: 229-66.

Chetaille P, Preuss C, Burkhard S, Cote JM, Houde C, Castilloux J, *et al.* Mutations in SGOL1 cause a novel cohesinopathy affecting heart and gut rhythm. *Nat Genet* 2014; 46(11): 1245-9.

Chiang C, Litingtung Y, Lee E, Young KE, Corden JL, Westphal H, *et al.* Cyclopia and defective axial patterning in mice lacking Sonic hedgehog gene function. *Nature* 1996; 383(6599): 407-13.

Cotney J, Muhle RA, Sanders SJ, Liu L, Willsey AJ, Niu W, *et al.* The autism-associated chromatin modifier CHD8 regulates other autism risk genes during human neurodevelopment. *Nat Commun* 2015; 6: 6404.

Cotton AM, Ge B, Light N, Adoue V, Pastinen T, Brown CJ. Analysis of expressed SNPs identifies variable extents of expression from the human inactive X chromosome. *Genome Biol* 2013; 14(11): R122.

De Franco E, Watson RA, Weninger WJ, Wong CC, Flanagan SE, Caswell R, *et al.* A Specific CNOT1 Mutation Results in a Novel Syndrome of Pancreatic Agenesis and Holoprosencephaly through Impaired Pancreatic and Neurological Development. *Am J Hum Genet* 2019.

Deardorff MA, Bando M, Nakato R, Watrin E, Itoh T, Minamino M, *et al.* HDAC8 mutations in Cornelia de Lange syndrome affect the cohesin acetylation cycle. *Nature* 2012a; 489(7415): 313-7.

Deardorff MA, Kaur M, Yaeger D, Rampuria A, Korolev S, Pie J, *et al.* Mutations in cohesin complex members SMC3 and SMC1A cause a mild variant of cornelia de Lange syndrome with predominant mental retardation. *Am J Hum Genet* 2007; 80(3): 485-94.

Deardorff MA, Wilde JJ, Albrecht M, Dickinson E, Tennstedt S, Braunholz D, *et al.* RAD21 mutations cause a human cohesinopathy. *Am J Hum Genet* 2012b; 90(6): 1014-27.

Dubourg C, Carre W, Hamdi-Roze H, Mouden C, Roume J, Abdelmajid B, *et al.* Mutational Spectrum in Holoprosencephaly Shows That FGF is a New Major Signaling Pathway. *Hum Mutat* 2016; 37(12): 1329-39.

Echelard Y, Epstein DJ, St-Jacques B, Shen L, Mohler J, McMahon JA, *et al.* Sonic hedgehog, a member of a family of putative signaling molecules, is implicated in the regulation of CNS polarity. *Cell* 1993; 75(7): 1417-30.

Everson JL, Fink DM, Yoon JW, Leslie EJ, Kietzman HW, Ansen-Wilson LJ, *et al.* Sonic Hedgehog regulation of Foxf2 promotes cranial neural crest mesenchyme proliferation and is disrupted in cleft lip morphogenesis. *Development* 2017.

Firth HV, Richards SM, Bevan AP, Clayton S, Corpas M, Rajan D, *et al.* DECIPHER: Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources. *Am J Hum Genet* 2009; 84(4): 524-33.

Geng X, Oliver G. Pathogenesis of holoprosencephaly. *J Clin Invest* 2009; 119(6): 1403-13.

Gil-Rodriguez MC, Deardorff MA, Ansari M, Tan CA, Parenti I, Baquero-Montoya C, *et al.* De novo heterozygous mutations in SMC3 cause a range of Cornelia de Lange syndrome-overlapping phenotypes. *Hum Mutat* 2015; 36(4): 454-62.

Goldstein JH, Tim-Aroon T, Shieh J, Merrill M, Deeb KK, Zhang S, *et al.* Novel SMC1A frameshift mutations in children with developmental delay and epilepsy. *Eur J Med Genet* 2015; 58(10): 562-8.

Gordillo M, Vega H, Trainer AH, Hou F, Sakai N, Luque R, *et al.* The molecular mechanism underlying Roberts syndrome involves loss of ESCO2 acetyltransferase activity. *Hum Mol Genet* 2008; 17(14): 2172-80.

Hahn JS, Barnes PD, Clegg NJ, Stashinko EE. Septopreoptic holoprosencephaly: a mild subtype associated with midline craniofacial anomalies. *AJNR Am J Neuroradiol* 2010; 31(9): 1596-601.

Heyne GW, Melberg CG, Doroodchi P, Parins KF, Kietzman HW, Everson JL, *et al.* Definition of critical periods for Hedgehog pathway antagonist-induced holoprosencephaly, cleft lip, and cleft palate. *PLoS One* 2015a; 10(3): e0120517.

Heyne GW, Plisch EH, Melberg CG, Sandgren EP, Peter JA, Lipinski RJ. A Simple and Reliable Method for Early Pregnancy Detection in Inbred Mice. *J Am Assoc Lab Anim Sci* 2015b; 54(4): 368-71.

Hong S, Hu P, Marino J, Hufnagel SB, Hopkin RJ, Toromanovic A, *et al.* Dominant-negative kinase domain mutations in FGFR1 can explain the clinical severity of Hartsfield syndrome. *Hum Mol Genet* 2016; 25(10): 1912-22.

Hoppman-Chaney N, Jang JS, Jen J, Babovic-Vuksanovic D, Hodge JC. In-frame multi-exon deletion of SMC1A in a severely affected female with Cornelia de Lange Syndrome. *Am J Med Genet A* 2012; 158A(1): 193-8.

Houtmeyers R, Tchouate Gankam O, Glanville-Jones HA, Van den Bosch B, Chappell A, Barratt KS, *et al.* *Zic2* mutation causes holoprosencephaly via disruption of NODAL signalling. *Hum Mol Genet* 2016; 25(18): 3946-59.

Huisman SA, Redeker EJ, Maas SM, Mannens MM, Hennekam RC. High rate of mosaicism in individuals with Cornelia de Lange syndrome. *Journal of medical genetics* 2013; 50(5): 339-44.

Izumi K, Nakato R, Zhang Z, Edmondson AC, Noon S, Dulik MC, *et al.* Germline gain-of-function mutations in *AFF4* cause a developmental syndrome functionally linking the super elongation complex and cohesin. *Nat Genet* 2015; 47(4): 338-44.

Jansen S, Kleefstra T, Willemsen MH, de Vries P, Pfundt R, Hehir-Kwa JY, *et al.* De novo loss-of-function mutations in X-linked *SMC1A* cause severe ID and therapy-resistant epilepsy in females: expanding the phenotypic spectrum. *Clin Genet* 2016; 90(5): 413-9.

Kircher M, Witten DM, Jain P, O'Roak BJ, Cooper GM, Shendure J. A general framework for estimating the relative pathogenicity of human genetic variants. *Nat Genet* 2014; 46(3): 310-5.

Kline AD, Moss JF, Selicorni A, Bisgaard AM, Deardorff MA, Gillett PM, *et al.* Diagnosis and management of Cornelia de Lange syndrome: first international consensus statement. *Nat Rev Genet* 2018; 19(10): 649-66.

Krantz ID, McCallum J, DeScipio C, Kaur M, Gillis LA, Yaeger D, *et al.* Cornelia de Lange syndrome is caused by mutations in *NIPBL*, the human homolog of *Drosophila melanogaster* Nipped-B. *Nat Genet* 2004; 36(6): 631-5.

Kruszka P, Berger SI, Weiss K, Everson JL, Martinez AF, Hong S, *et al.* CCR4-NOT transcription complex, subunit 1 (*CNOT1*) Variant Associated with Holoprosencephaly. *Am J Hum Genet* 2019.

Kruszka P, Martinez AF, Muenke M. Molecular testing in holoprosencephaly. *Am J Med Genet C Semin Med Genet* 2018; 178(2): 187-93.

Kruszka PMM. Syndromes Associated with Holoprosencephaly. *American Journal of Medical Genetics Part C: Seminars in Medical Genetics* 2018.

Lebrun N, Lebon S, Jeannet PY, Jacquemont S, Billuart P, Bienvenu T. Early-onset encephalopathy with epilepsy associated with a novel splice site mutation in SMC1A. *Am J Med Genet A* 2015; 167A(12): 3076-81.

Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E, Fennell T, *et al.* Analysis of protein-coding genetic variation in 60,706 humans. *Nature* 2016; 536(7616): 285-91.

Matsunaga E, Shiota K. Holoprosencephaly in human embryos: epidemiologic studies of 150 cases. *Teratology* 1977; 16(3): 261-72.

McBrien J, Crolla JA, Huang S, Kelleher J, Gleeson J, Lynch SA. Further case of microdeletion of 8q24 with phenotype overlapping Langer-Giedion without TRPS1 deletion. *Am J Med Genet A* 2008; 146A(12): 1587-92.

Mehta GD, Kumar R, Srivastava S, Ghosh SK. Cohesin: functions beyond sister chromatid cohesion. *FEBS Lett* 2013; 587(15): 2299-312.

Minor A, Shinawi M, Hogue JS, Vineyard M, Hamlin DR, Tan C, *et al.* Two novel RAD21 mutations in patients with mild Cornelia de Lange syndrome-like presentation and report of the first familial case. *Gene* 2014; 537(2): 279-84.

Mullegama SV, Klein SD, Mulatinho MV, Senaratne TN, Singh K, Center UCG, *et al.* De novo loss-of-function variants in STAG2 are associated with developmental delay, microcephaly, and congenital anomalies. *Am J Med Genet A* 2017; 173(5): 1319-27.

Mullegama SV, Klein SD, Signer RH, Center UCG, Vilain E, Martinez-Agosto JA. Mutations in STAG2 cause an X-linked cohesinopathy associated with undergrowth, developmental delay, and dysmorphia: Expanding the phenotype in males. *Mol Genet Genomic Med* 2019; 7(2): e00501.

Musio A, Selicorni A, Focarelli ML, Gervasini C, Milani D, Russo S, *et al.* X-linked Cornelia de Lange syndrome owing to SMC1L1 mutations. *Nat Genet* 2006; 38(5): 528-30.

Olley G, Ansari M, Bengani H, Grimes GR, Rhodes J, von Kriegsheim A, *et al.* BRD4 interacts with NIPBL and BRD4 is mutated in a Cornelia de Lange-like syndrome. *Nat Genet* 2018; 50(3): 329-32.

Pineda-Alvarez DE, Dubourg C, David V, Roessler E, Muenke M. Current recommendations for the molecular evaluation of newly diagnosed holoprosencephaly patients. *Am J Med Genet C Semin Med Genet* 2010; 154C(1): 93-101.

Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, *et al.* Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genetics in medicine : official journal of the American College of Medical Genetics* 2015; 17(5): 405-24.

Roessler E, Hu P, Muenke M. Holoprosencephaly in the genomics era. *Am J Med Genet C Semin Med Genet* 2018.

Roessler E, Hu P., Muenke M. Holoprosencephaly in the genomics era. *American Journal of Medical Genetics Part C (Seminars in Medical Genetics)* 2018.

Roessler E, Ma Y, Ouspenskaia MV, Lacbawan F, Bendavid C, Dubourg C, *et al.* Truncating loss-of-function mutations of DISP1 contribute to holoprosencephaly-like microform features in humans. *Hum Genet* 2009; 125(4): 393-400.

Roessler E, Muenke M. The molecular genetics of holoprosencephaly. *Am J Med Genet C Semin Med Genet* 2010; 154C(1): 52-61.

Sasaki H, Nishizaki Y, Hui C, Nakafuku M, Kondoh H. Regulation of Gli2 and Gli3 activities by an amino-terminal repression domain: implication of Gli2 and Gli3 as primary mediators of Shh signaling. *Development* 1999; 126(17): 3915-24.

Simonis N, Migeotte I, Lambert N, Perazzolo C, de Silva DC, Dimitrov B, *et al.* FGFR1 mutations cause Hartsfield syndrome, the unique association of holoprosencephaly and ectrodactyly. *Journal of medical genetics* 2013; 50(9): 585-92.

Soardi FC, Machado-Silva A, Linhares ND, Zheng G, Qu Q, Pena HB, *et al.* Familial STAG2 germline mutation defines a new human cohesinopathy. *NPJ Genom Med* 2017; 2: 7.

Sobreira N, Schiettecatte F, Valle D, Hamosh A. GeneMatcher: a matching tool for connecting investigators with an interest in the same gene. *Hum Mutat* 2015; 36(10): 928-30.

Solomon BD, Bear KA, Wyllie A, Keaton AA, Dubourg C, David V, *et al.* Genotypic and phenotypic analysis of 396 individuals with mutations in Sonic Hedgehog. *Journal of medical genetics* 2012; 49(7): 473-9.

Symonds JD, Joss S, Metcalfe KA, Somarathi S, Cruden J, Devlin AM, *et al.* Heterozygous truncation mutations of the SMC1A gene cause a severe early onset epilepsy with cluster seizures in females: Detailed phenotyping of 10 new cases. *Epilepsia* 2017; 58(4): 565-75.

Warr N, Powles-Glover N, Chappell A, Robson J, Norris D, Arkell RM. Zic2-associated holoprosencephaly is caused by a transient defect in the organizer region during gastrulation.

Hum Mol Genet 2008; 17(19): 2986-96.

Wuyts W, Roland D, Ludecke HJ, Wauters J, Foulon M, Van Hul W, *et al.* Multiple exostoses, mental retardation, hypertrichosis, and brain abnormalities in a boy with a de novo 8q24 submicroscopic interstitial deletion. American journal of medical genetics 2002; 113(4): 326-32.

Yuan B, Neira J, Pehlivan D, Santiago-Sim T, Song X, Rosenfeld J, *et al.* Clinical exome sequencing reveals locus heterogeneity and phenotypic variability of cohesinopathies. Genetics in medicine : official journal of the American College of Medical Genetics 2019; 21(3): 663-75.

Yuan B, Pehlivan D, Karaca E, Patel N, Charng WL, Gambin T, *et al.* Global transcriptional disturbances underlie Cornelia de Lange syndrome and related phenotypes. J Clin Invest 2015; 125(2): 636-51.

FIGURE LEGENDS

Figure 1. Patient images referenced from Table 1: A) Patient 3 with alobar HPE and a c.436C>T p.(Arg146*) variant in *STAG2*; B) Patient 5 with microform HPE and a c.2898_2899del p.(Glu968Serfs*15) in *STAG2*; C) Patient 2 with semilobar HPE and a c.205C>T p.(Arg69*) variant in *STAG2*; D) Patient 9 with semilobar HPE and a c.2683C>G (p.Arg895Gly) variant in *SMC1A*; E) Patient 7 with MIHV HPE and a c.3285+1G>C variant in *SMC1A*; F) Patient 8 with microform HPE and a c.1495C>T:p.(Arg499*) variant in *SMC1A*; G) Patient 15 with semilobar HPE and a *SMC3* variant c.1138_1152del p.(Gly380_Gln384del). HPE (holoprosencephaly); MIHV (middle interhemispheric variant)

Figure 2. Gestational day (GD) 8.25 mouse embryos were stained by *in situ* hybridization to determine gene expression patterns. A ventral view is shown for whole mounts. Transverse sections through the prosencephalic neural folds (at the level of the dashed line in schematic) were stained to visualize gene expression in specific cellular compartments. nf – neural folds, h – heart, ne – neuroectoderm, hm – head mesenchyme, eem – extra-embryonic membranes. Scale bar = 100 μ m.

Figure 3. Neural stem cells expressing Sh*SMC1A* or Non Silencing control (NS Ctrl) are analyzed by RT-qPCR 48h after transfection. Gene expression results are shown for genes previously described as genetic causes of HPE. Results are expressed over *SNAPIN*. The mean of the signals obtained from three independent experiments is shown. The error bars represent the SD. Asterisk indicates statistical significance (p value) as evaluated by Unpaired Two Tailed t-test analysis. Non statistically significant p values are indicated in brackets.

*= $P < 0.05$; **= $P < 0.01$.

Figure 4. Neural stem cells expressing Sh*STAG2* or Non Silencing control (NS Ctrl) are analyzed by RT-qPCR 72h after transfection. Gene expression results are shown for genes previously described as genetic causes of HPE. Gene expression results are expressed over *SNAPIN*. The mean of the signals obtained from three independent experiments is shown. The error bars represent the SD. Asterisk indicates statistical significance (p value) as evaluated by Unpaired Two Tailed t-test analysis. Non statistically significant p values are indicated in brackets.

= $P < 0.01$; **= $P < 0.0001$.

Table 1. Individuals with holoprosencephaly and variants in Cohesin Complex genes.

Patient ID	Gene	Variant	hg19/GRCh37 human reference genome	Inheritance	CADD score	Age	HPE type
1	<i>STAG2</i>	c.3034C>T p.(R1012*)	chrX-123217380-C-T	de novo	53	newborn	alobar
2	<i>STAG2</i>	c.205C>T p.(Arg69*)	chrX-123164892-C-T	de novo	27	2 years	semilobar
3	<i>STAG2</i>	c.436C>T p.(R146*)	chrX-123176469-C-T	singleton	38	32-week gestation	alobar
4	<i>STAG2</i>	c.2533+1G>A	chrX-123205174-G-A	maternal	34	Newborn/deceased	semilobar
5	<i>STAG2</i>	c.2898_2899del p.(Glu968Serfs*15)	chrX-123215352-123215353	de novo	34	12 months	microform
6	<i>STAG2</i>	c.775C>T p.(Arg259*)	chrX-123181311-C-T	de novo	36	9.5 years	septo-optic dysplasia
7	<i>SMC1A</i>	c.3285+1G>C	chrX-53409426-C-G	de novo	25.1	15 months	MIHV
8	<i>SMC1A</i>	c.1495C>T p.(Arg499*)	chrX-53436043-G-A	singleton	39	16.5 months	microform
9	<i>SMC1A</i>	c.2683C>G (p.Arg895Gly)	chrX-53423417-G-C	de novo	28.5	6 years	semilobar/lobar
10	<i>SMC1A</i>	c.2394delA; p.(Lys798Asnfs*31)	chrX-53430524	de novo	35	3 years	semilobar
11	<i>SMC1A</i>	c.2834delG; p.(Gly945Alafs*19)	chrX-53423175	de novo	35	20 months	semilobar
12	<i>RAD2</i>	c.1548delinsTC	chr8-	paternal	35	7 years	MIHV

	<i>I</i>	p.Glu518Argfs*19	117862929	y inherited			
13	<i>RAD2 I</i>	c.589C>T p.(Gln197*)	chr8- 117869605- G-A	unknown	38		HPE
14	<i>RAD2 I</i>	c.1217_1224del p.(Lys406Argfs*4)	chr8- 117864885	unknown		2 years	HPE
15	<i>SMC3</i>	c.1138_1152del p.(Gly380_Gln384del)	chr10- 112343987- GG...AG (15 bp)	de novo	21.9	Termination after 21 weeks	Semilobar

MIHV, middle interhemispheric variant type holoprosencephaly; CADD, Combined Annotation-Dependent Depletion

Table 2. Phenotype details of individuals with loss of function variants in *STAG2*.

	Present Study						Mullegama et al. 2016	Aoi et al. 2019		Yuan et al. 2019		
	patient 1	patient 2	patient 3	patient 4	patient 5	patient 6		patient 1	patient 2	patient 1	patient 2	patient 3
variant	c.3034C>T p.(R1012*)	c.205C>T p.(Arg69*)	c.436C>T:p.(R146*)	c.2533+1G>A	c.2898_2899del; p.(Glu968Serfs*15)	c.775C>T p.(Arg259*)	c.205C>T; p.(Arg69*)	c.3097C>T, p.(Arg1033*)	c.2229C>T, p.(Trp743*)	c.418C>T; p.Q140*	c.1605T>A p.C535*	c.1658_1660delins T; p.K533Ifs*6
inheritance	<i>de novo</i>	<i>de novo</i>	singleton	maternal	<i>de novo</i>	<i>de novo</i>	<i>de novo</i>	<i>de novo</i>	<i>de novo</i>	<i>de novo</i>	<i>de novo</i>	<i>de novo</i>
sex	female	female	female	female	female	female	female	male	female	female	female	female
age	newborn	2 years	32-week gestation	newborn/deceased	12 months	9.5 years	8 years	fetus	7 years	3.7 years	4.5 years	1.9 years
brain MRI/HPE type	alobar	semilobar	alobar ^a	semilobar	microform	septo-optic dysplasia	dysgenesis of the splenium of the corpus callosum	HPE (unspecified)	white matter hypoplasia	NR	NR	microform; agenesis of corpus callosum; colpocephaly
developmental delay	NA	global	NA	NA	+	intellectual disability; motor delay;	speech	NR	intellectual disability; developmental delay	motor and speech delay	intellectual disability; motor and speech delay	intellectual disability; motor and speech delay
craniofacial anomalies	midline cleft lip/palate	cleft palate; micrognathia	Cyclopia; absent nose, microsomia, hypognathia	-	NR	-	submucous cleft palate	cleft lip/palate	cleft palate	-	micrognathia	single central incisor; micrognathia
microcephaly	+	+	+	severe	+	-	+	NR	-	-	+	+
ear anomalies and hearing	low set	-	hypoplastic right ear	NR	NR	-	bilateral microtia with hearing loss	NR	hearing loss	dysmorphic ears	microtia, right; conductive hearing loss	dysmorphic ears
vertebral anomalies	lumbar spina bifida	-	T7-T10 hemivertebrae	NR	NR	NR	thoracic hemivertebrae and butterfly vertebrae	NR	thoracic hemivertebrae	vertebral clefts	NR	+
congenital heart disease	NR	patent foramen ovale and patent ductus arteriosus	ventricular septal defect	hypoplastic left heart; DORV	-	ventricular septal defect	ventricular septal defect	hypoplastic left heart	-	hypoplastic left heart	NR	NR
growth delay	NR	+	NA	NA	+	-		NR	short stature	-	+	+
limb anomalies	-	-	NR	-	NR	left hip dysplasia	bilateral fifth finger clinodactyly	NR	NR	-	fifth finger clinodactyly	-
other	gastroesophageal reflux and has a G-tube and Nissen fundoplication		duodenal atresia			bilateral optic nerve hypoplasia			seizure disorder	seizure disorder		seizure disorder

Double outlet right ventricle, DORV; holoprosencephaly, HPE; magnetic resonance imaging, MRI ; NA non-applicable; NR, not reported;

^aautopsy finding

Table 3. Phenotype details of individuals with variants in *SMC1A*.

	Present Study					Symonds et al., 2017	Jansen et al., 2016	Goldstein et al., 2015	Lebrun et al., 2015	Hoppman-Chaney et al., 2011
	Patient 7	Patient 8	Patient 9	Patient 10	Patient 11	n=10	n=2	n=2	n=1	n=1
variant	c.3285+1G>C	c.1495C>T;p.(Arg499*)	c.2683C>G (p.Arg895Gly)	c.2394delA; p.(Lys798Asnfs*31)	c.2834delG; p.(Gly945Alafs*19)	truncating variants (n=10)	truncating variants (n=2)	truncating variants (n=2)	c.1911 + 1G > T	8.2kb deletion in <i>SMC1A</i> ; 45.X[7]/46,XX[23]
inheritance	<i>de novo</i>	singleton	<i>de novo</i>	<i>de novo</i>	<i>de novo</i>	<i>de novo</i> 10/10	<i>de novo</i> 2/2	<i>de novo</i> 2/2	<i>de novo</i>	<i>de novo</i>
sex	female	female	female	female	female	female 10/10	female 2/2	female 2/2	female	female
age	15 months	16.5 months	6 years	3 years	20 months	11 months – 14 years	14-46 years	3-4 years	7 years	10 years
brain MRI	MIHV HPE	triventricular ectasia	semilobar/lobar HPE	semilobar HPE	semilobar HPE	semilobar HPE 1/10; thin corpus callosum 1/10	enlarged ventricles and cerebellar vermis hypotrophy (1/2)	thinning of corpus callosum 1/2	small frontal lobes, thin corpus callosum	semilobar HPE
developmental delay	+	+	+	+	+	10/10	2/2	2/2	+	+
craniofacial anomalies	NR	single central incisor; depressed nasal bridge	brachycephaly, synophrys, arched eyebrows, long eyelashes	synophrys; long eyelashes; upturned nose	sloping forehead, metopic ridging, upslanting palpebral fissures, midface flattening, bitemporal narrowing	cleft palate 2/10	cleft palate 1/2	0/2	retrognathia	skull asymmetry with right-sided flattening, prominent metopic suture, and bitemporal narrowing
microcephaly	+	+	+	+	+	average Z-score - 3.0 (9/9)	1/2	0/2	+	+
ear anomalies and hearing	NR	NR	NR	prominent ears	NR	posteriorly rotated ears (3/10)	Small ears and prominent anti-helix 1/2	0/2	-	-
vertebral anomalies	spina bifida (L-spine)	NR	NR	NR	NR	bifid thoracic vertebrae 2/10	Scoliosis 2/2	0	-	T7-T12 butterfly vertebrae and partial hemivertebrae
congenital heart disease	-	-	NR	-	patent foramen ovale	4/10	0/2	0/2	-	tetralogy of Fallot
growth delay	+	+	-	+	NR	average Z-score - 3.0 (9/9)	2/2	1/2	+	+
limb anomalies	NR	small hands	small hands; proximal implant of thumbs	small hands/feet	NR	minor limb anomalies 7/10	small hands 2/2	small hands/feet 1/2	small hands/feet	multiple minor limb anomalies
other	NR	seizure disorder; periodic fevers	seizure disorder; swallowing problems; congenital hip dysplasia; visual impairment	seizure disorder; feeding problems	seizure disorder	seizure disorder 9/9	seizure disorder 2/2	seizure disorder 2/2	seizure disorder, gastroesophageal reflux	

Holoprosencephaly, HPE: middle interhemispheric variant, MIHV; not reported, NR;

Table 4. Phenotype details of individuals with loss of function variants in *RAD21*.

	Present Study			Boyle et al., 2017	Minor et al., 2014		Deardorff et al., 2012		McBrien et al., 2008	Wuyts et al., 2002
	Patient 12	Patient 13	Patient 14		Patient 1	Patient 2	Patient 1	Patient 4		
variant	c.1548delinsTC p.Glu518Argfs*19	c.589C>T p.(Gln197*)	c.1217_1224del p.(Lys406Argfs*4)	c.704delG p.(Ser235Ilefs*19) ^b	heterozygous 665 base pair deletion including exon 13	c.592_593dup p.Ser198Argfs*6	heterozygous chr8:117,708,713- 121,024,193 (hg18) deletion ^c	heterozygous chr8: 116,950,003- 118,944,486 (hg18) deletion ^c	heterozygous chr8:117,640,909- 119,330,085 (hg18) deletion ^c	heterozygous chr8:117237- 12263162 (hg18) deletion ^c
inheritance	paternal ^a	(Hoppman- Chaney <i>et al.</i> , 2012)unknown	unknown	maternal	maternal	not found in mother; paternal sample unavailable	<i>de novo</i>	NR	<i>de novo</i>	<i>de novo</i>
sex	female	male	male	female	male	male	male	NR	male	male
age	7 years	14 years	2 years	26 years	3 years	12 years	7 years	NR	26 months	18 years
brain MRI	MIHV	HPE nonspecified			normal	NR	NR	NR	NR	focal hypersignal T2 weight images at level of tu- cinereum
developmental delay	+	+	+	+	+	+	-	cognitive delay	borderline	+
craniofacial anomalies	submucous cleft palate; synophrys, hypertelorism	hypotelorism, upturned nose, long philtrum	cleft palate	long philtrum, thin upper lip vermillion, short nose with upturned nasal tip (from images)	scaphocephaly, coarse facial features, frontal bossing, mild synophrys, right ptosis, depressed nasal bridge, short nose, micrognathia	brachycephaly; synophrys; anteverted nose; long philtrum; hirsutism	full arched eyebrows; synophrys, cleft palate	thick eyebrows	prominent metopic ridge; thick eyebrows	synophrys; philtrum, a thin vermillion border; hirsutism
microcephaly	NR	+		+	-	+	+	-	+	-
ear anomalies and hearing				-	posteriorly rotated ears	lowset and posteriorly rotated ears	-	-	NR	-
vertebral anomalies	NR	NR		NR	NR	NR	thoracic vertebral cleft	NR	hemivertebrae at T10 and T11	kyphosis
congenital heart disease	-	NR		-	NR	NR	-	-	patent foramen ovale	NR
growth delay				-	+	-	-	+	-	-
limb anomalies				5 th finger clinodactyly	minor hand and feet anomalies	minor hand and feet anomalies	minor hand and feet anomalies	proximal thumb	minor hand and feet anomalies	clinodactyly finger
other		seizure disorder			hypospadias; bifid scrotum; undescended testes; inguinal hernia		exostoses	exostoses	bifid scrotum; exostoses	seizure diso- exostoses

^aFather of proband is affected with synophrys, and a submucous cleft palate

^bMother affected with microcephaly and facial features consistent with CdLS

^c*RAD21* is only cohesin complex gene in minimal overlapping interval (*RAD21, EIF3H, UTP23, SLC30A8, MED30, EXT1, RAD21-AS1, AARD*)

Table 5.

	Present Study	Gil-Rodríguez et al., 2015
	Patient 15	n=16
variant	c.1138_1152del p.(Gly380_Gln384del)	missense (9/16); inframe deletions/duplications (6/16); nonsense (1/16)
inheritance	<i>de novo</i>	<i>de novo</i> (10/10)
sex	male	female 7/16
age	fetus	NR
brain imaging	semilobar HPE	corpus callosum dysgenesis (2/11); porencephalic cyst (1/11)
developmental delay	NA	intellectual disability (13/13)
craniofacial anomalies	median cleft lip	cleft palate 1/14; synophrys (11/15); thick eyebrows (9/13); anteverted nostrils (8/14); thin upper lip vermilion (13/16)
microcephaly	NR	6/12
ear anomalies and hearing	NR	low set ears (6/11); hearing loss 7/13
vertebral anomalies	NR	butterfly vertebrae (1/12); scoliosis (1/12)
congenital heart disease	tetralogy of Fallot	9/16
growth delay	NA	height Z-score < -3.0 (6/16); weight Z-score < -3.0 (5/16)
limb anomalies	hand/feet cutaneous syndactyly; ulnar deviation of 2 nd digit of hands bilaterally; proximally set thumbs	small hands (11/14); small feet (11/13); proximally set thumbs (12/16)
other	hypospadias; anal atresia	seizures (3/12)

Holoprosencephaly, HPE; non-applicable, NA